FDA, EMA to share information on generic drug application inspections

The U.S. Food and Drug Administration and the European Medicines Agency have launched a joint initiative to share information on inspections of bioequivalence studies submitted for generic drug approvals, according to a press release. The collaboration will provide a mechanism to conduct joint facility inspections for generic drug applications submitted to both agencies, the release said. Key objectives of the initiative are to streamline information regarding inspections of bioequivalence studies for generic drug applications; share information about negative inspection outcomes; conduct joint inspections at worldwide facilities; and provide training opportunities (Read more...)

Full Story →